Literature DB >> 18957310

Structurally based epitope analysis of major histocompatibility complex class I-related chain A (MICA) antibody specificity patterns.

Rene J Duquesnoy1, Justin Mostecki, Jayasree Hariharan, Ivan Balazs.   

Abstract

Recent studies have suggested a clinical significance to the detection of anti-major histocompatibility complex class I-related chain A (MICA) antibodies in transplantation. We have developed an eplet-based version of the HLAMatchmaker algorithm to assess the epitope specificity of these antibodies. Molecular viewing of the MICA structure and the determination of amino acid sequence differences between MICA alleles has yielded a repertoire of 38 potentially immunogenic MICA eplets. These eplets are based on the functional epitope structure that considers a configuration of amino acids within a 3-Angstrom radius of an antibody-accessible polymorphic residue on the molecular surface. In this study MICA-reactive sera were screened in Luminex assays with single MICA allele panels and analyzed with HLAMatchmaker. We identified reactivity patterns that correspond to eplet-specific antibodies to identify of unacceptable MICA mismatches including those alleles that have not been tested with the serum. In conclusion, HLAMatchmaker is a useful algorithm to analyze the reactivity patterns of anti-MICA antibodies and the determination of MICA mismatch acceptability at the structural level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18957310      PMCID: PMC2636556          DOI: 10.1016/j.humimm.2008.10.003

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  30 in total

1.  Complex structure of the activating immunoreceptor NKG2D and its MHC class I-like ligand MICA.

Authors:  P Li; D L Morris; B E Willcox; A Steinle; T Spies; R K Strong
Journal:  Nat Immunol       Date:  2001-05       Impact factor: 25.606

2.  Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family.

Authors:  A Steinle; P Li; D L Morris; V Groh; L L Lanier; R K Strong; T Spies
Journal:  Immunogenetics       Date:  2001 May-Jun       Impact factor: 2.846

Review 3.  The MIC gene family.

Authors:  S Bahram; T Spies
Journal:  Res Immunol       Date:  1996-06

4.  Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium.

Authors:  V Groh; S Bahram; S Bauer; A Herman; M Beauchamp; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

5.  MICA is a target for complement-dependent cytotoxicity with mouse monoclonal antibodies and human alloantibodies.

Authors:  Yizhou Zou; Fariba Mirbaha; Ana Lazaro; Yanzheng Zhang; Bhavna Lavingia; Peter Stastny
Journal:  Hum Immunol       Date:  2002-01       Impact factor: 2.850

6.  Allelic repertoire of the human MHC class I MICA gene.

Authors:  N Fodil; L Laloux; V Wanner; P Pellet; G Hauptmann; N Mizuki; H Inoko; T Spies; I Theodorou; S Bahram
Journal:  Immunogenetics       Date:  1996       Impact factor: 2.846

Review 7.  Relevance of MICA and other non-HLA antibodies in clinical transplantation.

Authors:  Suchitra Sumitran-Holgersson
Journal:  Curr Opin Immunol       Date:  2008-08-12       Impact factor: 7.486

8.  A second lineage of mammalian major histocompatibility complex class I genes.

Authors:  S Bahram; M Bresnahan; D E Geraghty; T Spies
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

9.  IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex.

Authors:  James Robinson; Matthew J Waller; Peter Parham; Natasja de Groot; Ronald Bontrop; Lorna J Kennedy; Peter Stoehr; Steven G E Marsh
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

10.  Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts.

Authors:  S Sumitran-Holgersson; H E Wilczek; J Holgersson; K Söderström
Journal:  Transplantation       Date:  2002-07-27       Impact factor: 4.939

View more
  6 in total

1.  Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control [version 2; peer review: 2 approved].

Authors:  Mathieu Bléry; Manel Mrabet-Kraiem; Ariane Morel; Florence Lhospice; Delphine Bregeon; Cécile Bonnafous; Laurent Gauthier; Benjamin Rossi; Romain Remark; Stéphanie Cornen; Nadia Anceriz; Nicolas Viaud; Sylvia Trichard; Sabrina Carpentier; Alix Joulin-Giet; Gwendoline Grondin; Veronika Liptakova; Younghoon Kim; Laurent Daniel; Aurélie Haffner; Nicolas Macagno; Laurent Pouyet; Ivan Perrot; Carine Paturel; Yannis Morel; Alexander Steinle; François Romagné; Emilie Narni-Mancinelli; Eric Vivier
Journal:  Open Res Eur       Date:  2021-10-27

2.  Why can sensitization by an HLA-DR2 mismatch lead to antibodies that react also with HLA-DR1?

Authors:  Marilyn Marrari; Rene J Duquesnoy
Journal:  Hum Immunol       Date:  2009-03-09       Impact factor: 2.850

3.  Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes.

Authors:  Olivia R Blume; Sarah E Yost; Bruce Kaplan
Journal:  J Transplant       Date:  2012-03-24

4.  Acute Antibody-Mediated Rejection in Presence of MICA-DSA and Successful Renal Re-Transplant with Negative-MICA Virtual Crossmatch.

Authors:  Yingzi Ming; Juan Hu; Qizhi Luo; Xiang Ding; Weiguang Luo; Quan Zhuang; Yizhou Zou
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

Review 5.  MICA and NKG2D: Is There an Impact on Kidney Transplant Outcome?

Authors:  Matilde Risti; Maria da Graça Bicalho
Journal:  Front Immunol       Date:  2017-02-27       Impact factor: 7.561

6.  Humoral alloimmunity in transplantation: relevance of HLA epitope antigenicity and immunogenicity.

Authors:  René J Duquesnoy
Journal:  Front Immunol       Date:  2011-11-08       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.